Biofrontera AG continued to adhere to its forecast for fiscal year 2022. Thus, the Group expects sales of EUR 24 to 27 million and positive EBITDA in 2022, provided that the encouraging business performance of the first nine months will continue.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.51 EUR | -1.40% | -48.41% | -58.32% |
May. 15 | Earnings Flash (BFRI) BIOFRONTERA Reports Q1 Revenue $7.9M, vs. Street Est of $10.9M | MT |
Apr. 30 | Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-58.32% | 11.45M | |
+34.35% | 705B | |
+29.39% | 583B | |
-3.49% | 364B | |
+20.15% | 332B | |
+6.19% | 291B | |
+14.11% | 238B | |
-3.03% | 210B | |
+10.02% | 209B | |
+9.21% | 169B |
- Stock Market
- Equities
- B8FK Stock
- News Biofrontera AG
- Biofrontera Ag Continues to Adhere to Forecast for Fiscal Year 2022